Roche’s VENTANA PD-L1 (SP263) Assay has received CE IVD approval to identify patients with locally advanced and metastatic NSCLC eligible for Libtayo, based on results of the phase III EMPOWER-Lung 1.
MD Anderson Cancer Center announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies.
OU Health Stephenson Cancer Center joined Caris’ Precision Oncology Alliance, a network of 70 cancer institutions committed to utilizing clinical data to advance patient care and outcomes.
Strata Oncology Inc announced the integration of discrete genomic data from its StrataNGS NGS-based tumor profiling with the University of Wisconsin Carbone Cancer Center and UW Health Epic genomics module.
Indivumed GmbH and CELLphenomics GmbH have formed a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets.
FDA approved Enhertu (fam-trastuzumab-deruxtecan-nxki) for unresectable or metastatic HER2-low breast cancer.
FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
FDA approved Pemazyre (pemigatinib), a selective fibroblast growth factor receptor inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
FDA approved Imbruvica (ibrutinib) for pediatric patients 1 year of age or older with chronic graft versus host disease after failure of 1 or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension.
On August 5, 2022, FDA approved Nubeqa (darolutamide) tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).
